Microspheres and Nanoparticles
On this page
Direct answer
Microspheres are matrix-type spherical particles of 1-1,000 micrometres; nanoparticles are submicron carriers below about 1,000 nanometres, both built to control where a drug goes and how fast it leaves. Microspheres dominate as biodegradable polymeric depots: poly(lactic-co-glycolic acid) (PLGA) and polylactide microspheres release drugs for weeks to months — risperidone two-weekly, octreotide monthly, leuprolide one- to four-monthly, naltrexone monthly — made by solvent evaporation from oil-in-water emulsions for hydrophobic drugs, double water-in-oil-in-water emulsions for peptides, or spray drying. Their release is characteristically biphasic: an initial burst from surface drug, then a slower phase of diffusion plus polymer erosion, tuned by the lactide:glycolide ratio (50:50 degrades fastest). Nanoparticles cover polymeric particles, solid lipid nanoparticles, nanostructured lipid carriers and drug nanocrystals — pure drug milled to hundreds of nanometres whose dissolution rate rises with surface area per the Noyes-Whitney equation, rescuing poorly soluble drugs like aprepitant and sirolimus; size also steers biodistribution, from renal clearance below about 10 nanometres to tumour extravasation around 100-200 nanometres.
What you must remember
- Size definitions: microparticles 1-1,000 micrometres; nanoparticles 10-1,000 nanometres; nanosuspensions typically 100-500 nanometres of pure drug with stabiliser.
- Matrix versus reservoir: microspheres disperse drug through a polymer matrix; microcapsules surround a core with a coat — an exam distinction that decides whole MCQs.
- Polymer logic: PLGA/PLA are biodegradable, hydrolyse to lactic and glycolic acids, and release faster at 50:50 lactide:glycolide than glycolide-poor grades; release spans days to months.
- Biphasic release: initial burst (surface drug) then diffusion-and-erosion plateau — the shape examiners ask candidates to sketch and label.
- Preparation map: o/w solvent evaporation (hydrophobic drugs), w/o/w double emulsion (proteins and peptides), spray drying, coacervation; nanoparticles by nanoprecipitation, emulsification, or wet milling for nanocrystals.
- Noyes-Whitney: dissolution rate = D × A × (Cs − C) / h — nanonisation raises surface area A and shrinks diffusion layer thickness h, the quantitative argument for nanocrystals.
- Size-biodistribution rules of thumb: below about 10 nm renal clearance; around 100-200 nm leaky-tumour extravasation; larger particles land in liver and spleen; opsonisation drives RES uptake unless PEGylated.
- Characterisation: size and distribution (laser diffraction, dynamic light scattering), zeta potential, morphology (SEM/TEM), entrapment efficiency, in vitro release; a zeta magnitude near ±30 mV is the classic colloidal-stability heuristic.
Two patients, two depots
A man with schizophrenia on risperidone microspheres arrives for his two-weekly injection. Why a depot at all: adherence in psychosis is fragile, and converting a daily tablet into a fortnightly intramuscular dose moves compliance from the patient's memory to the clinic calendar; the label's fine print even recommends oral coverage during the first weeks while the initial release profile establishes. The microspheres were made by double emulsion — peptide-class sensitivity demands gentle processing — and inside the muscle they release with the textbook biphasic curve: a small early burst, then steady diffusion-and-degradation output that pharmacokinetics flattens into a plateau. The detail examiners reward: changing the lactide:glycolide ratio or polymer molecular weight moves the plateau by weeks — one platform serves one-month and three-month leuprolide products.
Contrast an oral nanocrystal. Aprepitant, poorly soluble and slow to dissolve as a conventional tablet, is wet-milled with stabilisers into submicron crystals; by the Noyes-Whitney relation the dissolution rate climbs with surface area and the shortened diffusion path, so bioavailability no longer depends on a heavy meal. No polymer, no targeting — pure physical chemistry. The two technologies bracket the chapter's idea: size and architecture are formulation variables as real as excipients, with depot duration bought with microns and dissolution rate bought with nanometres.
Where students slip
Microsphere versus microcapsule is the first separator: matrix dispersion versus core-shell reservoir, and mixing them collapses the classification question. Second, the burst release is often misread as a defect; it is intrinsic to surface-localised drug and is managed, not eliminated — indeed, depot antipsychotics plan oral supplementation around it. Third, nanosuspensions are confused with polymeric nanoparticles: a nanosuspension is essentially pure drug plus stabiliser, nothing polymeric at all, and its entire rationale is dissolution-rate physics. Fourth, the claim that nanoparticles "target tumours" needs the honest mechanism — passive extravasation through leaky endothelium with poor lymphatic drainage, effective for a size window near 100-200 nanometres — rather than a homing fiction. Finally, sterilisation: most depots are manufactured aseptically or gamma-treated with validated stability, because you cannot autoclave a polymer matrix that is designed to hydrolyse.
Frequently asked questions
How do microspheres differ from microcapsules?
Microspheres are homogeneous polymer matrices with drug dispersed throughout; microcapsules are reservoir systems with a distinct core surrounded by a coating that controls release.
Why is PLGA the standard depot polymer?
It biodegrades to endogenous acids, its rate is tunable through lactide:glycolide ratio and molecular weight, and its safety record supports weeks-to-months release.
What causes the initial burst in depot release?
Drug sitting at or near the particle surface dissolves immediately upon hydration, producing a rapid early release before diffusion and polymer erosion establish the slower phase.
How do drug nanocrystals improve bioavailability?
Submicron size massively increases dissolution rate through surface area and a thinner diffusion layer (Noyes-Whitney), overcoming the dissolution-limited absorption of poorly soluble drugs.
Which marketed products illustrate each class?
Risperidone, octreotide, leuprolide and naltrexone PLGA depots; aprepitant and sirolimus nanocrystal products — names worth quoting.